Abstract
Purpose
The aim of this study was to evaluate the contrast enhancement, pharmacokinetics, dialyzability, and safety of gadodiamide in patients on hemodialysis.
Materials and methods
Thirteen hemodialysis patients with abdominal disease were examined after receiving intravenous gadodiamide (0.1 mmol/kg body weight) by magnetic resonance imaging (MRI) and were dialyzed at l, 3, 5, and 8 days. Blood samples were obtained immediately before, during, and at the end of the first hemodialysis session and immediately before and at the end of the next three sessions. The complete blood count, blood biochemistry, β2-microglobulin, and gadolinium were measured. Dialysis of urea, creatinine, and gadolinium during the first hemodialysis session was assessed. Precontrast and postcontrast MRI and Gd-enhanced MR angiography (MRA) images were reviewed and visually evaluated by two radiologists; their evaluation was based on consensus.
Results
Gadodiamide did not cause any changes in renal function. An average of 73.8%, 92.4%, and 98.9% of the gadodiamide dose was eliminated by the end of the first, second, and third hemodialysis sessions, respectively. The average half-time of gadodiamide was 1.93 h (SD 0.55). The mean clearance of gadodiamide during hemodialysis was 63.5 ml/min (SD 21.9). There were no side effects related to the injection of gadodiamide. In all cases, diagnosable MRI and MRA images were obtained after gadodiamide injection in the hemodialysis patients.
Conclusion
In hemodialysis patients, gadodiamide achieves diagnosable images. It is dialyzable and can be used safely without measures to increase excretion.
Similar content being viewed by others
References
J Haustein HP Niendorf G Krestin T Louton G Schuhmann-Giampiere W Clauss et al. (1992) ArticleTitleRenal tolerance of gadolinium-DTPA/dimeglumine in patients with chronic renal failure Invest Radiol 27 153–6 Occurrence Handle1601607 Occurrence Handle1:STN:280:DyaK383ptVOnug%3D%3D
TM Arsenault JW Marsh J Goodman A Weaver RL Ehman BF King (1993) ArticleTitleAssessment of gadolinium toxity in patients with renal insufficiency (abstract) Radiology 189 225
S Okada K Katagiri T Kumazaki H Yokoyama (2001) ArticleTitleSafety of gadolinium contrast agent in hemodialysis patients Acta Radiol 42 339–41 Occurrence Handle11350296 Occurrence Handle1:STN:280:DC%2BD3M3lt1SjsQ%3D%3D
HJ Weinmann RC Brasch WR Press GE Wesby (1984) ArticleTitleCharacteristics of gadolinium DTPA complex: a potential NMR contrast agent AJR Am J Roentgenol 142 619–24 Occurrence Handle6607655 Occurrence Handle1:STN:280:DyaL2c7isVyhsg%3D%3D
M Van Wagner M O'Toole D Worah PT Leese SC Quay (1991) ArticleTitleA phase clinical trial with gadodiamide, a nonionic magnetic resonance imaging enhancement agent Invest Radiol 26 980–6 Occurrence Handle10.1097/00004424-199111000-00010
TH Von Krahe R Gots K Lackner J Haustein U Klemenz P Landwehr et al. (1992) ArticleTitleThe pharmacokinetics of gadolinium DTPA in the presence of chronic renal sufficiency requiring dialysis (English abstract) Rofo Fortshr Roentgenstr 156 523–6 Occurrence Handle10.1055/s-2008-1032936
JM Lazarus RM Hakim (1991) Medical aspects of hemodialysis BM Brenner FC Rector (Eds) The kidney EditionNumber4th ed Saunders Philadelphia 2223–33
MR Prince (1996) ArticleTitleNephrotoxicity of high-dose gadolinium compared with iodinated contrast J Magn Reson Imaging 1 162–6
MF Twendle (1992) ArticleTitlePhysicochemical properties of gadoteridol and other magnetic resonance contrast agents Invest Radiol 27 IssueIDSuppl S2–6
PL Choyke JA Frank D Webb MR Filling Katz (1990) ArticleTitleCase report: gadopentate dimeglumine enhanced MRI in an anephric patient on dialysis Clin Radiol 41 430–2 Occurrence Handle2383962 Occurrence Handle1:STN:280:DyaK3czksFGqtw%3D%3D Occurrence Handle10.1016/S0009-9260(05)80609-9
HS Tomsen (2003) ArticleTitleGuidelines for contrast media from the Europian Society of Urogenital Radiology AJR Am J Roentgenol 181 1463–71
SK Morcos HS Thomden JA Webb (2002) ArticleTitleDialysis and contrast media Eur Radiol 12 3026–30 Occurrence Handle12439587
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Saitoh, T., Hayasaka, K., Tanaka, Y. et al. Dialyzability of gadodiamide in hemodialysis patients. Radiat Med 24, 445–451 (2006). https://doi.org/10.1007/s11604-006-0055-9
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11604-006-0055-9